Boston Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Boston Advisors’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,236	Closed	-$390K	–	669
2015 Q4	$390K	Buy	7,236 +225	+3%	+$11.8K	0.01%	521
2015 Q3	$346K	Buy	+7,011	New	+$402K	0.01%	631
2015 Q2	–	Sell	-3,774	Closed	-$217K	–	667
2015 Q1	$217K	Buy	+3,774	New	+$206K	0.01%	628

Other funds holding IHE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

ARS Wealth Advisors St. Petersburg, Florida $556M AUM 30.03% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

SFI

SPC Financial Inc Rockville, Maryland $1.28B AUM 12.6% 1-Year Est. Return

Spinnaker Trust Portland, Maine $1.81B AUM 17.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

EAMA

EFG Asset Management (Americas) Miami, Florida $579M AUM 24.22% 1-Year Est. Return

Boston Advisors's IHE Position: Q1 2016 in Review

Boston Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2016, closing a stake of 7,236 shares — an estimated $390K sold.

Boston Advisors first reported a position in IHE in Q1 2015 and held it in 3 quarters. The position peaked at $390K in Q4 2015. 91 funds tracked by Wall St. Rank hold IHE as of Q1 2016.

Boston Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2016 after selling out during the quarter.
Boston Advisors sold 7,236 iShares US Pharmaceuticals ETF shares in Q1 2016, an estimated $390K.
Boston Advisors first reported a position in iShares US Pharmaceuticals ETF in Q1 2015 and held it in 3 quarters.
Boston Advisors's iShares US Pharmaceuticals ETF position peaked at $390K in Q4 2015.
91 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2016.

Based on Boston Advisors's 13F filing for Q1 2016, filed 20 Apr 2016.